Loading company…
RegImmune develops biopharmaceutical therapies for immune disorders, including graft-versus-host disease.
RegImmune develops therapies intended to modulate immune responses and address disorders such as graft-versus-host disease. Founded in 2006, the company is based in Tokyo, Japan, and was at Series E. In May 2017, it raised JPY 650 million from Hiroshima Venture Capital and Mitsubishi UFJ Capital, among other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in